Freezing Cancer in Its Tracks: Cryoablation Shows Promise Against Limited Metastases

When cancer spreads beyond its original site, most patients and their doctors brace for a long, systemic battle. Yet a small but growing body of research suggests that for a select group of patients whose disease has spread only to a handful of locations, destroying those few tumors directly can meaningfully extend survival. A new study from Denmark adds fresh evidence that one of the most minimally invasive ways to do this, freezing tumors through the skin, can achieve durable local control with remarkably few complications, even in patients too frail for surgery or further radiation therapy.

The research, published in CVIR Oncology by a team led by Maria Tækker of Aarhus University Hospital, examined percutaneous cryoablation, a technique in which thin, needle-like probes are inserted through the skin directly into a tumor under computed tomography guidance. Once the probes are in position, pressurized argon gas is circulated through their tips, dropping the temperature at the tumor to at least minus 40 degrees Celsius. At that extreme cold, ice crystals form inside and around cancer cells, rupturing membranes and cutting off the blood supply, ultimately killing the tissue through a process of controlled necrosis. Because the expanding ice ball is visible on CT scans as it grows, the radiologist can watch the frozen zone engulf the tumor in real time, ensuring the lethal cold extends at least five millimeters beyond the tumor’s edge while sparing nearby healthy structures.

This real-time visibility is one of cryoablation’s most significant advantages over competing ablative technologies, and it carries a second benefit that is easy to overlook: the procedure can be repeated. Unlike stereotactic body radiation therapy, where cumulative radiation dose limits how many times a region can be treated, or surgery, where each operation adds scar tissue and risk, cryoablation leaves tissue in a state that can safely tolerate another freeze cycle if a tumor returns. For patients with oligometastatic disease, the intermediate state between localized and widespread cancer in which only a limited number of metastases exist in a few organ sites, that repeatability could prove decisive.

The Danish team set out to test exactly that proposition in a group of patients who had run out of conventional options. Between December 2016 and February 2022, sixteen patients with fewer than three histologically verified metastases each were selected for treatment at a single center. Crucially, every case was reviewed by a multidisciplinary team of oncologists, surgeons, pathologists, and radiologists, and all of the patients had already completed treatment for their primary cancers. Many carried significant comorbidities: the most common were hypertension and diabetes, and the average score on the American Society of Anesthesiologists physical status scale, which grades surgical risk, was 2.6, indicating severe systemic disease in several participants. These were not healthy patients; they were people whose age or health made surgery, additional radiation, or more chemotherapy too dangerous, leaving cryoablation as the only feasible curative-intent option.

The technical execution of the procedures reflects the maturity the field has reached. A senior radiologist with a decade of experience in CT-guided interventions performed the ablations, most of them, 73.7 percent, under conscious sedation rather than general anesthesia. Using an argon-based cryoablation system with sealed 14- or 17-gauge cryoprobes, the team created ice balls that covered each tumor with a margin of at least five millimeters. Standard treatments used a double freeze-thaw cycle of ten minutes of freezing followed by eight minutes of thawing, a rhythm that exploits the way repeated freezing damages cells more thoroughly than a single cycle. Lymph node metastases received a triple freeze-thaw protocol, and when tumors sat close to vulnerable structures, the team used hydrodisplacement, injecting fluid to physically push organs such as the bowel away from the freezing zone.

The results, drawn from fifteen patients and sixteen metastases with complete follow-up, are striking for a cohort this fragile. The median tumor size was 18 millimeters, though lesions ranged from 6 to 60 millimeters, and the primary cancers originated in the kidney, lung, and breast. After a single cryoablation treatment, 80 percent of patients achieved local tumor control at a median follow-up of 23.6 months. Three patients whose tumors progressed underwent repeat ablations, and after these retreatments the so-called secondary efficacy rate rose to 93 percent at a median follow-up of 28.7 months. In other words, even when the first freeze failed to eradicate a lesion permanently, freezing it again usually finished the job, validating the technique’s key selling point of repeatability.

The safety profile was equally encouraging. Ninety percent of patients went home the same day. Of the nineteen treatments performed, only two produced post-procedural complications, and just one patient needed overnight hospitalization for monitoring. Graded on the Common Terminology Criteria for Adverse Events scale, complications were limited to grade 1 in 16 percent of procedures and grade 2 in 5 percent, with nothing more severe, and no complication required further intervention. For a population of comorbid patients with stage IV cancer, avoiding the morbidity of surgery or the accumulating toxicity of repeat radiation while still achieving local tumor control represents a genuine clinical gain.

Survival figures rounded out the picture. At one year, 93 percent of patients were alive; at two years, 72 percent; and at three years, 63 percent. The deaths that occurred were attributed to progression of the primary cancers rather than to the procedure itself. These numbers sit comfortably within the range reported by comparable studies, which have shown two-year overall survival of 82 to 94 percent and three-year survival of roughly 62 to 82 percent for metastasis-directed cryoablation. A recent retrospective analysis of 511 patients with lung metastases by Gits and colleagues found no significant survival differences between sublobar resection, stereotactic body radiation therapy, and percutaneous ablation, suggesting that needle-based approaches can stand alongside established local therapies. Meanwhile, literature on radiation-directed treatment of oligometastases indicates that such metastasis-directed therapy may extend expected survival by up to fifteen months, underscoring the stakes of getting local control right.

The study’s authors are candid about its limits. With only fifteen analyzed patients, a retrospective design, and a single center, the findings cannot be generalized blindly, and the inclusion of patients with advanced cancer and high anesthetic risk scores may actually understate the survival that healthier candidates could expect. Tumor size also emerged as a question mark: prior research suggests lesions larger than 20 millimeters carry a higher risk of local progression after cryoablation, and while this study’s tumors ranged well beyond that threshold, the sample was too small to settle the matter. What the data do support is a consistent pattern across diverse anatomical sites, from kidneys and adrenal glands to retroperitoneal soft tissue, lymph nodes, and even the iliac bone, that percutaneous cryoablation is an effective and repeatable method for managing limited metastatic disease over at least a two-year horizon.

The broader significance of the work lies in what it offers patients who have been told their options are exhausted. For someone with two or three metastases and a heart too weak for surgery, a same-day procedure that freezes their tumors under light sedation, with a 93 percent chance of lasting local control after retreatment and no serious complications, changes the calculus of stage IV cancer. The researchers argue that future clinical trials should evaluate overall survival together with quality of life, since both metrics capture what matters most when life is extended at advanced disease stages. High-level randomized evidence comparing cryoablation directly with radiation therapy for oligometastatic disease is still missing, but studies like this one, built on careful multidisciplinary selection, standardized reporting, and honest accounting of failures, are laying the groundwork. For now, the message is simple and quietly revolutionary: sometimes the best answer to a spreading cancer is not more drugs or bigger operations, but a precisely guided blast of cold, delivered through a needle, and repeated as often as needed.

Subject of Research: Percutaneous cryoablation as metastasis-directed therapy for oligometastatic cancer

Article Title: Percutaneous imaging-guided cryoablation of oligometastases – a single-center experience

Article References: Tækker, M., Pietersen, P. I., Junker, T., Jensen, C. G., Vogsen, M., Rasmussen, B. S., Welch, B. T., Persson, G. F., Al-Mashhadi, R., & Graumann, O. (2025). Percutaneous imaging-guided cryoablation of oligometastases – a single-center experience. CVIR Oncology, 1(1), Article 11. https://doi.org/10.1007/s44343-025-00011-5

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00011-5

Keywords: cryoablation, oligometastatic disease, metastases, interventional radiology, CT guidance, cancer treatment, local tumor control, overall survival, minimally invasive therapy, kidney cancer, lung cancer, breast cancer